Daratumumab subcutaneous injection (Darzalex®) accepted for use within NHS Scotland

Following submission under the orphan medicine process, SMC has approved daratumumab in combination with bortezomib, thalidomide and dexamethasone for treatment of adult patients with newly diagnosed multiple myeloma and eligible for autologous stem cell transplant.

Scottish Medicines Consortium